ID: ALA10253

Max Phase: Preclinical

Molecular Formula: C24H23N3O3S2

Molecular Weight: 465.60

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCSc1ccnc(C[S+]([O-])c2nc3ccccc3n2COC(=O)c2ccccc2)c1C

Standard InChI:  InChI=1S/C24H23N3O3S2/c1-3-31-22-13-14-25-20(17(22)2)15-32(29)24-26-19-11-7-8-12-21(19)27(24)16-30-23(28)18-9-5-4-6-10-18/h4-14H,3,15-16H2,1-2H3

Standard InChI Key:  VCOUAFGUCLGZAE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 465.60

Molecular Weight (Monoisotopic): 465.1181

AlogP: 4.97

#Rotatable Bonds: 8

Polar Surface Area: 80.07

Molecular Species: NEUTRAL

HBA: 7

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.14

CX Basic pKa: 2.86

CX LogP: 5.26

CX LogD: 5.26

Aromatic Rings: 4

Heavy Atoms: 32

QED Weighted: 0.21

Np Likeness Score: -0.88

References

1. Sih JC, Im WB, Robert A, Graber DR, Blakeman DP..  (1991)  Studies on (H(+)-K+)-ATPase inhibitors of gastric acid secretion. Prodrugs of 2-[(2-pyridinylmethyl)sulfinyl]benzimidazole proton-pump inhibitors.,  34  (3): [PMID:1848293] [10.1021/jm00107a026]

Source

Source(1):

• Scientific Literature